Navigation Links
Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD)
Date:5/15/2008

GREEN BAY, Wis., May 15 /PRNewswire/ -- Omega 3 fatty acids bound to phospholipids deserves to be further considered as a credible natural alternative and may have beneficial effect on impulsivity in ADHD patients, recent in vivo French study reveals. While several studies have reported beneficial effects of omega-3 in hyperactivity, French researchers have hypothesized that Vectomega(R) could have specific positive effects on impulse control.

These research findings have led to the initiation of two multi-center studies currently underway in France and Germany utilizing Vectomega(R) on hyperactive children. Vectomega(R), a natural whole food Omega 3 fatty acid bound to phospholipids and peptides, is the end result of a French governmental research project.

In 2001, the French government solicited researchers throughout France to investigate potential uses of omega 3 fatty acids and phospholipids. Vectomega(R) is an extract of marine phospholipids complexed with EPA and DHA from salmon heads, the result of the research work by three, world-renowned scientists in the field of phospholipids and essential fatty acids, Professor Michel Linder, Professor Jacques Fanni, and Professor Michel Parmentier. Professor Linder will visit the United States to present at the 99th Annual AOCS Meeting to be held in Seattle May 18-21, 2008.

Vectomega(R), distributed exclusively in the United States by EuroPharma Inc, is a whole food omega-3 EPA/DHA complex which includes phospholipids and marine peptides as they naturally occur in salmon. Molecularly different from other omega-3's on the market, Vectomega(R) is said to be up to 10 to 50 times more absorbable across cellular membranes, using Caco-2 analysis, than other EPA/DHA products.

Vectomega(R) is extracted using a patented enzymatic and pure water innovation that extracts naturally occurring marine phospholipids with the omega-3 fatty acids, EPA and DHA. The extraction is carried out in less than an hour in an inert atmosphere at a temperature lower than 60 degrees C. The omega 3 fatty acids, EPA and DHA can be extracted maintaining their position on the triglyceride chain using this patented process and keeping their natural proportions and composition. This patented innovation, called vectorization, uses a gentle, cold water and enzyme process avoiding heat, solvents, and chemical modifications that are utilized to process all other fish oils. This patented process provides an excellent advantage for the consumer, as the finished phospholipid complex is in tablet form, requiring only one tablet per day, with no regurgitation or fishy after-taste.

"Omega 3 oils containing EPA/DHA have become increasingly popular in response to the growing body of science that validates their numerous health benefits, including heart health and cognitive function," stated Terry Lemerond, president of EuroPharma. "Vectomega(R) surpasses all other EPA/DHA products in terms of bioavailability, absorption and efficacy. Much of the value is lost in fish oils currently on the market because they are highly refined, distilled and deodorized by the use of extraction processes that use high temperatures, solvents and chemical modifications. Vectomega(R) is the only whole food omega 3 complex that is extracted from salmon in a natural process," said Lemerond.

Prevalence estimates of ADHD diagnosis in US school-aged children is 7.4% (4.7 million children) according to the CDC website. The nutritional supplement omega 3 category is reported to be a $7 billion dollar market. The vast benefits of omega 3 supplementation are widely studied and recognized by the media and consumers.

EuroPharma, Inc. a Green Bay, Wisconsin-based nutritional supplement supplier offering a full line of dietary supplements to health food stores, doctors and natural pharmacies throughout the US. EuroPharma's president, Terry Lemerond has over 40 years of industry experience and product development expertise and is the recipient of the 2008 Natural Products Association Industry Champion Award. The Natural Products Association Industry Champion Award recognizes individuals who have made notable contributions to the natural products industry above and beyond commercial success. For more information on Vectomega(R) or EuroPharma(R), please contact Lisa Joski at Ljoski@EuroPharmaUSA.com, 920-406-6506, or visit http://www.EuroPharmaUSA.com.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pregnant Women Need Omega-3 to Boost Infant Development
2. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
3. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
4. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
7. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
8. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Autism ... What are the key drugs marketed for ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device ... of chronic pain, today reported financial results for the three ... 2016 Accomplishment & Highlights: Achieved revenue ... of 228% as reported, over the prior year ... 612% over the prior year International revenue ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology:
(Date:2/24/2017)... Pekin, IL (PRWEB) , ... February 24, 2017 , ... ... in the 7th annual “Imagine Me Beyond What You See” body image mannequin art ... Professional’s Choice will be showcased and the winner revealed at the 31st annual iaedp ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
Breaking Medicine News(10 mins):